| 项目编号 | PRJCA050893 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 项目标题 | Astragalus membranaceus improves blood glucose and renal function in diabetic kidney disease mice via gut microbial metabolite axis | ||||||||||||
| 涉及领域 | Medical | ||||||||||||
| 数据类型 |
Metagenome
Metabonomics |
||||||||||||
| 物种名称 | |||||||||||||
| 描述信息 | Recent studies have demonstrated the therapeutic effects of Astragalus membranaceus on diabetic kidney disease (DKD); however, the underlying mechanisms remain insufficiently elucidated. In this study, a streptozotocin-induced DKD mouse model was established to evaluate the effects of Astragalus membranaceus extract (AME) on glycemic control, renal function, gut microbiota composition, and metabolic profiles. Biochemical analyses revealed that AME significantly attenuated hyperglycemia and restored renal function by reducing serum creatinine and blood urea nitrogen levels. Metagenomic sequencing demonstrated that AME reversed dysbiosis by suppressing pathogenic bacteria (e.g., Aerococcus urinaeequi) and enriching probiotics (e.g., Thomasclavelia cocleata). Furthermore, LC/MS-based metabolomics identified key metabolic pathways, including glycerophospholipid metabolism and bile acid synthesis, as potential mediators of the therapeutic effects of AME. These findings underscore the crucial role of the gut-renal axis in DKD and offer a mechanistic basis for the clinical application of AME. | ||||||||||||
| 样品范围 | Monoisolate | ||||||||||||
| 发布日期 | 2026-01-15 | ||||||||||||
| 出版信息 |
|
||||||||||||
| 项目资金来源 |
|
||||||||||||
| 提交者 | peipei Zhang (zhangpp0810@163.com) | ||||||||||||
| 提交单位 | China Pharmaceutical University | ||||||||||||
| 提交日期 | 2025-11-11 |
| 资源名称 | 描述 |
|---|---|
| BioSample (18) show | - |